NASDAQ:PACB Pacific Biosciences of California (PACB) Stock Price, News & Analysis $1.96 -0.01 (-0.51%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$1.92 -0.03 (-1.79%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Pacific Biosciences of California Stock (NASDAQ:PACB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PACB alerts:Sign Up Key Stats Today's Range$1.84▼$2.0050-Day Range$1.27▼$2.9052-Week Range$1.07▼$3.44Volume7.02 million shsAverage Volume12.62 million shsMarket Capitalization$613.34 millionP/E RatioN/ADividend YieldN/APrice Target$2.57Consensus RatingReduce Company Overview Pacific Biosciences of California, or PacBio, develops and sells DNA sequencing systems and related products for life science research and clinical applications. The company is known for its single-molecule real-time (SMRT) sequencing technology, which produces long reads that can help researchers study complex regions of the genome and identify genetic variations. Its portfolio includes HiFi sequencing systems such as the Revio and Vega platforms, along with instruments, consumables, software and services used to prepare, sequence and analyze genetic samples. PacBio also offers the Onso short-read sequencing platform. Founded in 2004 and headquartered in Menlo Park, California, PacBio serves customers in research institutions, universities, hospitals, biotechnology and pharmaceutical companies, and agricultural organizations around the world. Christian O. Henry is the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Pacific Biosciences of California Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScorePACB MarketRank™: 2.01257861635 of 5 starsPacific Biosciences of California scored higher than 40% of companies evaluated by MarketBeat, and ranked 672nd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingReduce Consensus RatingPacific Biosciences of California has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialPacific Biosciences of California has a consensus price target of $2.57, representing about 31.0% upside from its current price of $1.96.Amount of Analyst CoveragePacific Biosciences of California has only been the subject of 4 research reports in the past 90 days.Read more about Pacific Biosciences of California's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pacific Biosciences of California are expected to grow in the coming year, from ($0.51) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacific Biosciences of California is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacific Biosciences of California is -4.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.93% of the float of Pacific Biosciences of California has been sold short.Short Interest Ratio / Days to CoverPacific Biosciences of California has a short interest ratio ("days to cover") of 4.14.Change versus previous monthShort interest in Pacific Biosciences of California has recently increased by 14.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPacific Biosciences of California does not currently pay a dividend.Dividend GrowthPacific Biosciences of California does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.29 News SentimentPacific Biosciences of California has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Pacific Biosciences of California this week, compared to 3 articles on an average week.Search InterestOnly 14 people have searched for PACB on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Pacific Biosciences of California to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pacific Biosciences of California insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,088,654.00 in company stock.Percentage Held by Insiders3.70% of the stock of Pacific Biosciences of California is held by insiders.Percentage Held by InstitutionsPacific Biosciences of California has minimal institutional ownership at this time.Read more about Pacific Biosciences of California's insider trading history. Receive PACB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PACB Stock News HeadlinesUBS Group Issues Pessimistic Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock PriceNovember 11, 2026 | americanbankingnews.comPacific Biosciences Enters Agreement for At-the-Market Stock OfferingNovember 10, 2026 | tipranks.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 15 at 1:00 AM | Behind the Markets (Ad)UBS Adjusts Price Target on Pacific Biosciences of California to $2.70 From $3.05, Maintains Neutral RatingNovember 9, 2026 | marketscreener.comMPacific Biosciences of California, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 9, 2026 | seekingalpha.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Has Average Target Price of $1.71 According to AnalystsNovember 9, 2026 | americanbankingnews.comPacific Biosciences of California (NASDAQ:PACB) Stock Lifted to Hold by Wall Street ZenNovember 7, 2026 | americanbankingnews.comPacific Biosciences Q3: Another Revenue Guidance CutNovember 5, 2026 | seekingalpha.comSee More Headlines PACB Stock Analysis - Frequently Asked Questions How have PACB shares performed this year? Pacific Biosciences of California's stock was trading at $1.87 on January 1st, 2026. Since then, PACB stock has increased by 4.8% and is now trading at $1.96. How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its earnings results on Wednesday, November, 4th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.02. The biotechnology company had revenue of $40.56 million for the quarter, compared to analyst estimates of $39.31 million. Pacific Biosciences of California had a negative net margin of 81.31% and a negative trailing twelve-month return on equity of 5,752.12%. Read the conference call transcript. Does Pacific Biosciences of California have any subsidiaries? Pacific Biosciences of California subsidiaries include Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences Japan GK, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences UK Limited, and Pacific Biosciences International LLC. When did Pacific Biosciences of California IPO? Pacific Biosciences of California (PACB) raised $200 million in an IPO on Wednesday, October 27th 2010. The company issued 12,500,000 shares at $15.00-$17.00 per share. Who are Pacific Biosciences of California's major shareholders? Pacific Biosciences of California's top institutional shareholders include State Street Corp (1.93%), Sumitomo Mitsui Trust Group Inc. (1.59%), Carret Asset Management LLC (0.20%) and Voya Investment Management LLC (0.16%). Insiders that own company stock include Christian O Henry, Oene Mark Van, James R Gibson II, Jeff Eidel, Michele Farmer and Susan G Kim. View institutional ownership trends. How do I buy shares of Pacific Biosciences of California? Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pacific Biosciences of California own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pacific Biosciences of California investors own include CRISPR Therapeutics (CRSP), Invitae (NVTA), Tesla (TSLA), NVIDIA (NVDA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD) and Plug Power (PLUG). Company Calendar Last Earnings11/04/2026Today11/15/2026Stephens Annual Investment Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PACB's financial health is in the Green zone, according to TradeSmith. PACB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:PACB CIK1299130 Webwww.pacb.com Phone(650) 521-8000Fax302-636-5454Employees485Year Founded2004Price Target and Rating Average Price Target for Pacific Biosciences of California$2.57 High Price Target$3.00 Low Price Target$2.00 Potential Upside/Downside+31.0%Consensus RatingReduce Rating Score (0-4)1.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$546.38 million Net Margins-81.31% Pretax Margin-80.87% Return on Equity-5,752.12% Return on Assets-19.52% Debt Debt-to-Equity RatioN/A Current Ratio4.62 Quick Ratio4.03 Sales & Book Value Annual Sales$160.01 million Price / Sales3.83 Cash Flow$0.78 per share Price / Cash Flow2.50 Book Value($0.20) per share Price / Book-9.80Miscellaneous Outstanding Shares312,930,000Free Float301,349,000Market Cap$613.34 million OptionableOptionable Beta2.21 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PACB) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacific Biosciences of California With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PACB Stock Alerts